[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349381-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349381-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-peripheral-blood-based-approach-involving-vimentin-along-with-aurka-enabled-efficient-tracking-of-elusive-oct4sox2-expressing-disseminated-breast-cancer-stem-cells","A peripheral blood-based approach involving vimentin along with AURKA enabled efficient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells","","Breast cancer relapse is driven by clinically undetectable breast cancer stem cells (BCSCs), requiring translationally relevant markers for targeted tracking. This study evaluates Aurora kinase A (AURKA) as a detection tool for Oct4/Sox2-expressing disseminated BCSCs and explains limited benefits from AURKA inhibition. Flow cytometry and chromatin immunoprecipitation link Oct4/Sox2/AURKA expression via an Oct4/Sox2 threshold-dependent AURKA induction, while patient blood shows Oct4/Sox2+ cells lacking AURKA, highlighting dynamic marker profiles. Immunoprecipitation and immunofluorescence identify an AURKA–pNUMB axis associated with fate changes, and Oct4/Sox2/AURKA+ cells express vimentin. The work proposes a peripheral blood approach using AURKA and vimentin for BCSC tracking, supported by preliminary combined in vitro targeting that reduces stemness propensities and motivates clinical validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-peripheral-blood-based-approach-involving-vimentin-along-with-aurka-enabled-efficient-tracking-of-elusive-oct4sox2-expressing-disseminated-breast-cancer-stem-cells/349381/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-peripheral-blood-based-approach-involving-vimentin-along-with-aurka-enabled-efficient-tracking-of-elusive-oct4sox2-expressing-disseminated-breast-cancer-stem-cells/349381.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is tracking breast cancer stem cells important in therapy?","Question",{"text":63,"@type":64},"Therapeutic failure is linked to persistence of clinically undetectable BCSCs that drive relapse, and they can evade treatment due to quiescent behavior and resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study find about Oct4/Sox2 and AURKA expression?",{"text":68,"@type":64},"Flow cytometry and chromatin immunoprecipitation correlated Oct4/Sox2/AURKA expression, suggesting Oct4/Sox2 threshold-dependent AURKA induction.",{"name":70,"@type":61,"acceptedAnswer":71},"How do vimentin and an AURKA–pNUMB axis relate to BCSC fate?",{"text":72,"@type":64},"Immunoprecipitation/immunofluorescence indicated pAURKA interaction with fate-determinant pNUMB, and Oct4/Sox2/AURKA+ cells expressed vimentin, supporting a mesenchymal fate association.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349381,1790182400,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Bioscience Reports (2026) 46 BSR20253828 [https://doi.org/10.1042/BSR20253828](https://doi.org/10.1042/BSR20253828)  \nResearch Article  \nA peripheral blood-based approach involving vimentin along with AURKA enabled efﬁcient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells  \n Debomita Sengupta1,* ,  Debanjan Thakur1,* ,  Elizabeth Mahapatra1,2 ,  Salini Das1 , Jayanta Chakrabarti3 ,  Sagar Sen4 and  Sutapa Mukherjee1  \n1 Department of Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata 700026, India; 2 Department of Neurosurgery, The Houston Methodist Research Institute, Houston, Texas, U.S.A. ; 3 Director & HoD, Department of Surgical Oncology, Chittaranjan National Cancer Institute, Hazra Campus: 37, S. P. Mukherjee Road, Kolkata-700 026, INDIA, Newtown Campus: Street No. 299, DJ Block, Action Area 1D, Kolkata – 700160, INDIA; 4 Department of Surgical Oncology, Chittaranjan National Cancer Institute, Street No. 299, DJ Block, Action Area 1D, Kolkata – 700160, INDIA.  \nCorrespondence: Sutapa Mukherjee ([sutapamukherjee@cnci.ac.in](sutapamukherjee@cnci.ac.in)) or Debomita Sengupta (senguptaofﬁ[cial7@gmail.com](cial7@gmail.com))  \n*  \nThese authors contributed equally to this work and are joint ﬁrst authors.  \nA major impediment in the therapeutic success of breast cancer (BC) arises from the persistence of clinically undetectable breast cancer stem cells (BCSCs) that need addressal by targeting translationally relevant markers to restrain relapse. Aurora kinase A (AURKA), due to its negative prognostic effect, was considered in clinical trials yet showed an unappreciable response, highlighting the need for additional markers. The present study tried exploring AURKA as a tool of relevance to detect the abundance of  \nOct4/Sox2(octamer-binding transcription factor 4/sex-determining region Y-box 2)-expressing BCSCs. The purpose was to understand the underlying intricacies governing the limited success of AURKA inhibition and to seek an improved relevant marker profile for detecting disseminated BCSCs. Flow cytometry and chromatin immunoprecipitation assay findings correlated Oct4/Sox2/AURKA expression, proposing an Oct4/Sox2 threshold-dependent AURKA induction. Surprisingly, in BC patient blood, Oct4/Sox2+ve cells were apparently lacking AURKA, emphasizing marker profile dynamicity in disseminating BCSCs with transient cell fate alterations. Immunoprecipitation/immunofluorescence results highlighted an interaction of pAURKA with fate-determinant pNUMB, hinting toward the existence of an AURKA/pNUMB axis formesenchymal fate induction in breast cancer cells. Oct4/Sox2/AURKA+ve cells further expressed vimentin, highlighting a mesenchymal fate in BCSCs as evident from correlated Oct4/Sox2 and vimentin expression in patient blood. Hence, our study indicated an existing Oct4/Sox2/AURKA/pNUMB axis during transient mesenchymal differentiation of BCSCs and subsequently advocated for a peripheral blood-based approach using AURKA and vimentin for tracking BCSCs, thus supporting a co-targeting strategy. Preliminary in vitro intervention using combinatorial targeting of AURKA and vimentin reduced stemness propensities. Based on these interesting observations, further in-depth studies are warranted for clinical validation.  \nReceived: 17 July 2025  \nRevised: 28 February 2026  \nAccepted: 11 June 2026  \nVersion of Record published:  \n24 June 2026  \nIntroduction  \nBreast cancer is the leading cause of cancer-related death in women globally, as per GLOBOCAN 2022 [1] . A large percentage of patients who demonstrated apparent clinical remission present with disease  \n© 2026 The Author(s) . This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution 1 License 4 .0 (CC BY) .  \nBioscience Reports (2026) 46 BSR20253828 [https://doi.org/10.1042/BSR20253828](https","cbCaiebwBBNYnLlw","https://ap.wps.com/l/cbCaiebwBBNYnLlw","pdf",11189539,24,"English","# Introduction\n## Breast cancer recurrence and cancer stem cells\n## Role and limits of AURKA in breast cancer","[{\"question\":\"Why is tracking breast cancer stem cells important in therapy?\",\"answer\":\"Therapeutic failure is linked to persistence of clinically undetectable BCSCs that drive relapse, and they can evade treatment due to quiescent behavior and resistance.\"},{\"question\":\"What did the study find about Oct4/Sox2 and AURKA expression?\",\"answer\":\"Flow cytometry and chromatin immunoprecipitation correlated Oct4/Sox2/AURKA expression, suggesting Oct4/Sox2 threshold-dependent AURKA induction.\"},{\"question\":\"How do vimentin and an AURKA–pNUMB axis relate to BCSC fate?\",\"answer\":\"Immunoprecipitation/immunofluorescence indicated pAURKA interaction with fate-determinant pNUMB, and Oct4/Sox2/AURKA+ cells expressed vimentin, supporting a mesenchymal fate association.\"}]","A peripheral blood-based approach involving vimentin along with AURKA enabled efficient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells | PDF",1790083093,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e18b4ce264095e9717e2d14a5c3a598.webp",983,1301,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b0170c930332026b71668889fb60b05.webp",982,1299,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bef04161cdd8a4f4561541e16470b81.webp",981,1298,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d959113c6349347460d724241ac8e00.webp",980,1297]